Einzeltreffer — DigiBib

Background: Chronic pain is a major cause of suffering and disability and is often associated with psychiatric complications. Current treatments carry the risk of severe side effects and may lead to limited or no relief at all in a relevant portion of this patient population. Preliminary evidence suggests that classical psychedelics (e.g. LSD and psilocybin) may have analgesic effects in healthy volunteers, and in certain chronic pain conditions and observational studies reveal that they are used in naturalistic settings as a means to manage pain.

Methods: In order to gain insight on the effectiveness of such compounds in chronic pain conditions, we set up a survey addressed to chronic pain patients inquiring about psychedelic use and the relief levels achieved with both conventional treatments, full psychedelic doses and microdoses. We analysed data related to five conditions selected based on diagnostic homogeneity within each of them: fibromyalgia, arthritis, migraine, tension-type headache and sciatica.

Results: Except for sciatica, volunteers reported that psychedelics led to better pain relief compared to conventional medication in all examined conditions. More specifically, full doses performed better than conventional medication. Microdoses led to significantly better relief compared to conventional medication in migraines and achieved comparable relief in the remaining three categories. Implications for future research are discussed.

Conclusions: Full doses and microdoses may hold value in the treatment of some specific chronic pain conditions.

Significance: Psychedelic substances are receiving increasing attention from the scientific literature because of evidence showing beneficial effects on several measures related to mental health in clinical samples and healthy volunteers samples. Previous evidence suggests that people suffering from chronic pain are using psychedelics to seek relief and the present paper presents the results of a survey study investigating their use and analgesic effects among individuals suffering from fibromyalgia, arthritis, migraine, tension-type headache and sciatica.

Titel:	Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study.
Autor/in / Beteiligte Person:	Cavarra, M ; Mason, NL ; Kuypers, KPC ; Bonnelle, V ; Smith, WJ ; Feilding, A ; Kryskow, P ; Ramaekers, JG
Link:	Full Text Finder (Volltext)
Zeitschrift:	European journal of pain (London, England), Jg. 28 (2024), Heft 1, S. 153-165
Veröffentlichung:	2012- : Chichester, UK : Wiley ; <i>Original Publication</i>: London ; Philadelphia : Saunders, c1997-, 2024
Medientyp:	academicJournal
ISSN:	1532-2149 (electronic)
DOI:	10.1002/ejp.2171
Schlagwort:	Humans Chronic Disease Analgesics therapeutic use Hallucinogens adverse effects Chronic Pain drug therapy Fibromyalgia drug therapy Sciatica Tension-Type Headache Arthritis Migraine Disorders
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Eur J Pain] 2024 Jan; Vol. 28 (1), pp. 153-165. <i>Date of Electronic Publication: </i>2023 Aug 20. MeSH Terms: Hallucinogens* / adverse effects ; Chronic Pain* / drug therapy ; Fibromyalgia* / drug therapy ; Sciatica* ; Tension-Type Headache* ; Arthritis* ; Migraine Disorders* ; Humans ; Chronic Disease ; Analgesics / therapeutic use References: Andersson, M., Persson, M., & Kjellgren, A. (2017). Psychoactive substances as a last resort-A qualitative study of self-treatment of migraine and cluster headaches. Harm Reduction Journal, 14, 1-10. ; Bonnelle, V., Smith, W. J., Mason, N. L., Cavarra, M., Kryskow, P., Kuypers, K. P., Ramaekers, J. G., & Feilding, A. (2022). Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: A population survey. British Journal of Pain, 16(6), 619-631. ; Burke, A. L., Mathias, J. L., & Denson, L. A. (2015). Psychological functioning of people living with chronic pain: A meta-analytic review. British Journal of Clinical Psychology, 54(3), 345-360. ; Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F., Halberstadt, A., & Furnish, T. (2020). Chronic pain and psychedelics: A review and proposed mechanism of action. Regional Anesthesia & Pain Medicine, 45(7), 486-494. ; Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P., & Mento, C. (2022). Psychedelic-assisted psychotherapy-A systematic review of associated psychological interventions. Frontiers in Psychology, 2996, 1-21. ; Cohen, S. P., Vase, L., & Hooten, W. M. (2021). Chronic pain: An update on burden, best practices, and new advances. The Lancet, 397(10289), 2082-2097. ; Coussens, N. P., Sittampalam, G. S., Jonson, S. G., Hall, M. D., Gorby, H. E., Tamiz, A. P., McManus, O. B., Felder, C. C., & Rasmussen, K. (2019). The opioid crisis and the future of addiction and pain therapeutics. Journal of Pharmacology and Experimental Therapeutics, 371(2), 396-408. ; De Vos, C. M., Mason, N. L., & Kuypers, K. P. (2021). Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Frontiers in Psychiatry, 12, 724606. ; Dueñas, M., Ojeda, B., Salazar, A., Mico, J. A., & Failde, I. (2016). A review of chronic pain impact on patients, their social environment and the health care system. Journal of Pain Research, 9, 457-467. ; Edinoff, A. N., Fort, J. M., Singh, C., Wagner, S. E., Rodriguez, J. R., Johnson, C. A., Cornett, E. M., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022). Alternative options for complex, recurrent pain states using cannabinoids, psilocybin, and ketamine: A narrative review of clinical evidence. Neurology International, 14(2), 423-436. ; Elman, I., Pustilnik, A., & Borsook, D. (2022). Beating pain with psychedelics: Matter over mind? Neuroscience & Biobehavioral Reviews, 134, 104482. ; Els, C., Jackson, T. D., Kunyk, D., Lappi, V. G., Sonnenberg, B., Hagtvedt, R., Sharma, S., Kolahdooz, F., & Straube, S. (2017). Adverse events associated with medium-and long-term use of opioids for chronic non-cancer pain: An overview of Cochrane reviews. Cochrane Database of Systematic Reviews, 10, 1-16. ; Fanciullacci, M., Bene, E. D., Franchi, G., & Sicuteri, F. (1977). Phantom limb pain: Sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25). Headache: The Journal of Head and Face Pain, 17(3), 118-119. ; Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., Kamerman, P. R., Lund, K., Moore, A., Raja, S. N., Rice, A. S. C., Rowbotham, M., Sena, E., Siddall, P., Smith, B. H., & Wallace, M. (2015). Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. The Lancet Neurology, 14(2), 162-173. ; Flanagan, T. W., & Nichols, C. D. (2018). Psychedelics as anti-inflammatory agents. International Review of Psychiatry, 30(4), 363-375. ; Glynos, N. G., Pierce, J., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022). Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia. Journal of Psychoactive Drugs, 55, 1-12. ; Goldberg, D. S., & McGee, S. J. (2011). Pain as a global public health priority. BMC Public Health, 11(1), 1-5. ; Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. ; Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (1973). LSD-assisted psychotherapy in patients with terminal cancer. International Pharmacopsychiatry, 8(3), 129-144. https://doi.org/10.1159/000467984. ; Hall, A. M., Kamper, S. J., Maher, C. G., Latimer, J., Ferreira, M. L., & Nicholas, M. K. (2011). Symptoms of depression and stress mediate the effect of pain on disability. Pain, 152(5), 1044-1051. ; Hann, K. E., & McCracken, L. M. (2014). A systematic review of randomized controlled trials of acceptance and commitment therapy for adults with chronic pain: Outcome domains, design quality, and efficacy. Journal of Contextual Behavioral Science, 3(4), 217-227. ; Häuser, W., Petzke, F., & Fitzcharles, M. A. (2018). Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management-an overview of systematic reviews. European Journal of Pain, 22(3), 455-470. ; Hoffman, B. M., Papas, R. K., Chatkoff, D. K., & Kerns, R. D. (2007). Meta-analysis of psychological interventions for chronic low back pain. Health Psychology, 26(1), 1-9. ; Johannes, C. B., Le, T. K., Zhou, X., Johnston, J. A., & Dworkin, R. H. (2010). The prevalence of chronic pain in United States adults: Results of an internet-based survey. The Journal of Pain, 11(11), 1230-1239. ; Kast, E. (1967). Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly, 41(4), 646-657. ; Kast, E. C., & Collins, V. J. (1963). Study of lysergic acid diethylamide as an analgesic agent. Anesthesia and Analgesia, 43(3), 285-291. ; Kettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021). Psychedelic communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Frontiers in Pharmacology, 234, 234-254. ; Kirsch, I. (2018). Response expectancy and the placebo effect. International Review of Neurobiology, 138, 81-93. ; Kuypers, K. P. (2020). The therapeutic potential of microdosing psychedelics in depression. Therapeutic Advances in Psychopharmacology, 10, 1-15. ; Kuypers, K. P., Ng, L., Erritzoe, D., Knudsen, G. M., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019). Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 33(9), 1039-1057. ; Nijs, J., Malfliet, A., Ickmans, K., Baert, I., & Meeus, M. (2014). Treatment of central sensitization in patients with ‘unexplained’ chronic pain: An update. Expert Opinion on Pharmacotherapy, 15(12), 1671-1683. https://doi.org/10.1517/14656566.2014.925446. ; Okusanya, B. O., Lott, B. E., Ehiri, J., McClelland, J., & Rosales, C. (2022). Medical cannabis for the treatment of migraine in adults: A review of the evidence. Frontiers in Neurology, 13, 1-7. ; Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Liechti, M. E., Feilding, A., Holze, F., & Kuypers, K. P. (2021). A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of Psychopharmacology, 35(4), 398-405. ; Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & the Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. (2020). Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry, 177(5), 391-410. ; Schindler, E. A., Gottschalk, C. H., Weil, M. J., Shapiro, R. E., Wright, D. A., & Sewell, R. A. (2015). Indoleamine hallucinogens in cluster headache: Results of the clusterbusters medication use survey. Journal of Psychoactive Drugs, 47(5), 372-381. ; Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., Pittman, B. P., Cozzi, N. V., & D'Souza, D. C. (2021). Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics, 18(1), 534-543. ; Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920-1922. ; Soussan, C., & Kjellgren, A. (2016). The users of novel psychoactive substances: Online survey about their characteristics, attitudes and motivations. International Journal of Drug Policy, 32, 77-84. ; Voon, P., Karamouzian, M., & Kerr, T. (2017). Chronic pain and opioid misuse: A review of reviews. Substance Abuse Treatment, Prevention, and Policy, 12(1), 36. https://doi.org/10.1186/s13011-017-0120-7. ; Williams, A. C. D. C., Fisher, E., Hearn, L., & Eccleston, C. (2020). Psychological therapies for the management of chronic pain (excluding headache) in adults (review). Cochrane Database of Systematic Reviews, 11(11), CD007407. https://doi.org/10.1002/14651858.CD007407.pub4. ; Yekkirala, A. S., Roberson, D. P., Bean, B. P., & Woolf, C. J. (2017). Breaking barriers to novel analgesic drug development. Nature Reviews Drug Discovery, 16(8), 545-564. ; Zia, F. Z., Baumann, M. H., Belouin, S. J., Dworkin, R. H., Ghauri, M. H., Hendricks, P. S., Henningfield, J. E., Lanier, R. K., Ross, S., & Berger, A. (2023). Are psychedelic medicines the reset for chronic pain? Preliminary Findings and Research Needs. Neuropharmacology, 233, 109528. https://doi.org/10.1016/j.neuropharm.2023.109528. Substance Nomenclature: 0 (Hallucinogens) ; 0 (Analgesics) Entry Date(s): Date Created: 20230820 Date Completed: 20231216 Latest Revision: 20240103 Update Code: 20240104

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study.